9M 2023 Financial Overview

9M 2023: APPENDIX Strategic brands 5,000 4,000 3,000 2,000 1,000 Strategic brands revenue (Quarterly DKKm) vyepti™ 10,500 9,000 +7% reported 7,500 6,000 4,500 3,000 1,500 Brintellix® REXULTI™ vortioxetine Trintellix vortioxetine Abilify Maintena (aripiprazole prolonged-release suspension for injection Abilify Asimtufii (aripiprazole) Strategic brands revenue (9M-DKKM) +14% reported Comments · Strong performance across the strategic brands reaching DKK 10.1bn, representing a growth of 16% (+14% reported) in 9M 2023 +17% (+9% reported) in the United States +11% (+9% reported) in Europe • +7% (-2% reported) in International Markets Strong growth momentum is expected to continue 0 0 Q3.20 Q3.21 Q3.22 Q3.23 9M 2020 9M 2021 9M 2022 9M 2023 United States Europe International Markets 36 Unless otherwise stated, growth rates are at CER. 1) Quarter over quarter growth

View entire presentation